C. Fleurinck

Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

Steve Cunningham, Pedro A. Piedra, Federico Martinón‐Torres et al. · The Lancet Respiratory Medicine · 2020 · 132 citations · Full text

Medicine, Infectious Diseases, Pediatrics +15

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos et al. · Annals of the Rheumatic Diseases · 2023 · 106 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde et al. · Annals of the Rheumatic Diseases · 2023 · 50 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials

Matthew A. Brown, Martín Rudwaleit, F. van Gaalen et al. · Annals of the Rheumatic Diseases · 2024 · 33 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: <scp>Three‐Year</scp> Results From a Phase <scp>IIb</scp> Randomized Controlled Trial and Its <scp>Open‐Label</scp> Extension Study

Xenofon Baraliakos, Atul Deodhar, Maxime Dougados et al. · Arthritis & Rheumatology · 2022 · 29 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14